首页> 外文期刊>Nature >VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model
【24h】

VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model

机译:逆转录转运慢病毒载体的VEGF递送可延长小鼠ALS模型的存活率

获取原文
获取原文并翻译 | 示例
           

摘要

Amyotrophic lateral sclerosis (ALS) causes adult-onset, progressive motor neuron degeneration in the brain and spinal cord, resulting in paralysis and death three to five years after onset in most patients(1). ALS is still incurable, in part because its complex aetiology remains insufficiently understood. Recent reports have indicated that reduced levels of vascular endothelial growth factor ( VEGF), which is essential in angiogenesis and has also been implicated in neuroprotection(2-4), predispose mice and humans to ALS(5,6). However, the therapeutic potential of VEGF for the treatment of ALS has not previously been assessed. Here we report that a single injection of a VEGF-expressing lentiviral vector into various muscles delayed onset and slowed progression of ALS in mice engineered to overexpress the gene coding for the mutated G93A form of the superoxide dismutase-1 (SOD1(G93A)) (refs 7-10), even when treatment was only initiated at the onset of paralysis. VEGF treatment increased the life expectancy of ALS mice by 30 per cent without causing toxic side effects, thereby achieving one of the most effective therapies reported in the field so far.
机译:肌萎缩性侧索硬化症(ALS)导致成年发作的大脑和脊髓进行性运动神经元变性,导致大多数患者在发作后三到五年瘫痪并死亡(1)。 ALS仍然是无法治愈的,部分原因是对它的复杂病因尚缺乏足够的了解。最近的报道表明,降低的血管内皮生长因子(VEGF)水平在血管生成中至关重要,并且也与神经保护有关(2-4),这使小鼠和人类容易患ALS(5,6)。但是,以前尚未评估过VEGF在治疗ALS中的治疗潜力。在这里,我们报告说,在被设计成过表达编码超氧化物歧化酶-1(SOD1(G93A))的突变G93A形式的基因的小鼠中,将VEGF表达的慢病毒载体单次注射到各种肌肉中会延迟ALS的发作并减缓ALS的进展。 (参考文献7-10),即使仅在瘫痪发作时才开始治疗。 VEGF治疗可将ALS小鼠的预期寿命延长30%,而不会引起毒性副作用,从而成为迄今为止该领域报道的最有效的疗法之一。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号